HEPATOCELLULAR CANCER
Clinical trials for HEPATOCELLULAR CANCER explained in plain language.
Never miss a new study
Get alerted when new HEPATOCELLULAR CANCER trials appear
Sign up with your email to follow new studies for HEPATOCELLULAR CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to stop liver cancer return after surgery
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own immune cells combined with an immunotherapy drug (nivolumab) to prevent liver cancer or colorectal cancer that has spread to the liver from coming back after surgery. About 60 participants will receive the vaccine …
Matched conditions: HEPATOCELLULAR CANCER
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated May 01, 2026 15:27 UTC
-
New drug ABBV-324 enters first human tests for tough cancers
Disease control Recruiting nowThis early-stage study tests an experimental drug called ABBV-324 in about 232 adults with liver cancer (hepatocellular cancer) or a type of lung cancer (squamous non-small cell lung cancer). The main goals are to check safety and see if the drug shrinks tumors. Participants rece…
Matched conditions: HEPATOCELLULAR CANCER
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 29, 2026 15:14 UTC
-
Engineered immune cells take on hard-to-treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a personalized treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that have a specific marker called GPC3. The study includes adults with advanced liver cancer or other solid tumors that expr…
Matched conditions: HEPATOCELLULAR CANCER
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC
-
New pill plus immunotherapy shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental oral drug called 7HP349 (Alintegimod) combined with standard immunotherapy drugs (ipilimumab and nivolumab) in adults with advanced solid tumors like melanoma, lung, kidney, or liver cancer that have not responded to prior treatments. The goal is …
Matched conditions: HEPATOCELLULAR CANCER
Phase: PHASE1, PHASE2 • Sponsor: 7 Hills Pharma, LLC • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC